# BeyondSpring Pharmaceuticals

Source: https://onco.cc/companies/beyondspring/  
OnCo record `beyondspring` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BeyondSpring is a New York biotechnology company developing plinabulin, a microtubule-binding agent tested in phase 3 for chemotherapy-induced neutropenia and for non-small-cell lung cancer, which received a complete response letter from the FDA in 2021.

## Summary

BeyondSpring Pharmaceuticals, listed on Nasdaq, develops plinabulin, a small molecule that binds tubulin and triggers dendritic cell maturation. It ran phase 3 trials of plinabulin to prevent chemotherapy-induced neutropenia (PROTECTIVE-1 and 2) and, with docetaxel, in previously treated non-small-cell lung cancer (DUBLIN-3); the FDA issued a complete response letter for the neutropenia indication in 2021 asking for a second trial. OnCo records it as a registry sponsor of phase 3 cancer trials.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: BeyondSpring Pharmaceuticals Inc.; BeyondSpring
- Tags: ctgov-sponsor
- HQ: New York, NY
- Type: biotech
- Website: https://www.beyondspringpharma.com

## Sources

- Official website: https://www.beyondspringpharma.com
- ClinicalTrials.gov: trials led by BeyondSpring: https://clinicaltrials.gov/search?lead=BeyondSpring

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- terms: [Neutropenia](https://onco.cc/terms/neutropenia/)

---
JSON: https://onco.cc/api/v1/entities/beyondspring.json